These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10575579)

  • 1. Pregnancy rate in IVF rescue in high responders to human menopausal gonadotropin.
    Many A; Azem F; Lessing JB; Yovel I; Yavetz H; Amit A
    J Assist Reprod Genet; 1999 Nov; 16(10):520-2. PubMed ID: 10575579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoidance of cancellation of potential hyperstimulation cycles by conversion to in vitro fertilization-embryo transfer.
    Lessing JB; Amit A; Libal Y; Yovel I; Kogosowski A; Peyser MR
    Fertil Steril; 1991 Jul; 56(1):75-8. PubMed ID: 1906019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome.
    Tomazevic T; Meden-Vrtovec H
    J Assist Reprod Genet; 1996 Apr; 13(4):282-6. PubMed ID: 8777340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fresh versus frozen-thawed blastocyst transfer in high responders.
    Kalem Z; Namli Kalem M; Ruso H; Bakirarar B; Gurgan T
    Ginekol Pol; 2018; 89(8):407-413. PubMed ID: 30215458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
    Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
    J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization programme reduces the risk of ovarian hyperstimulation syndrome in high responders.
    Amit A; Yaron Y; Yovel I; Peyser MR; David MP; Botchan A; Lessing JB
    Hum Reprod; 1993 Aug; 8(8):1184-6. PubMed ID: 8408514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonist rescue of agonist IVF cycle at risk of OHSS: a case series.
    Martínez F; Mancini F; Solé M; José Gomez M; Beatriz Rodríguez D; Buxaderas R; Rodriguez I; Nolasc Barri P
    Gynecol Endocrinol; 2014 Feb; 30(2):145-8. PubMed ID: 24266696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing severe ovarian hyperstimulation syndrome in an in vitro fertilization/embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration.
    Vrtovec HM; Tomazevic T
    J Reprod Med; 1995 Jan; 40(1):37-40. PubMed ID: 7722973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.